- Home
- CREV vs QNRX Comparison
CREV vs QNRX Comparison
Compare CREV & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- QNRX
- Stock Information
- Founded
- CREV 2007
- QNRX 2018
- Country
- CREV Ireland
- QNRX United States
- Employees
- CREV N/A
- QNRX N/A
- Industry
- CREV
- QNRX Medical/Dental Instruments
- Sector
- CREV
- QNRX Health Care
- Exchange
- CREV Nasdaq
- QNRX Nasdaq
- Market Cap
- CREV 6.0M
- QNRX 5.5M
- IPO Year
- CREV N/A
- QNRX N/A
- Fundamental
- Price
- CREV $4.19
- QNRX $8.63
- Analyst Decision
- CREV
- QNRX
- Analyst Count
- CREV 0
- QNRX 0
- Target Price
- CREV N/A
- QNRX N/A
- AVG Volume (30 Days)
- CREV 705.7K
- QNRX 6.2K
- Earning Date
- CREV 05-14-2025
- QNRX 08-07-2025
- Dividend Yield
- CREV N/A
- QNRX N/A
- EPS Growth
- CREV N/A
- QNRX N/A
- EPS
- CREV N/A
- QNRX N/A
- Revenue
- CREV $39,261,077.00
- QNRX N/A
- Revenue This Year
- CREV $40.76
- QNRX N/A
- Revenue Next Year
- CREV $86.18
- QNRX N/A
- P/E Ratio
- CREV N/A
- QNRX N/A
- Revenue Growth
- CREV 41.52
- QNRX N/A
- 52 Week Low
- CREV $2.00
- QNRX $5.01
- 52 Week High
- CREV $14.19
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- CREV 61.02
- QNRX 48.98
- Support Level
- CREV $4.36
- QNRX $8.53
- Resistance Level
- CREV $5.99
- QNRX $9.20
- Average True Range (ATR)
- CREV 0.66
- QNRX 0.36
- MACD
- CREV 0.12
- QNRX -0.08
- Stochastic Oscillator
- CREV 61.78
- QNRX 19.63
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.